ライフサイエンスコーパス: positive symptom

1 hippocampal activity that is correlated with positive symptoms.

2 spindles correlated with greater severity of positive symptoms.

3 l striatum was correlated with the degree of positive symptoms.

4 induced cognitive deficits and negative and positive symptoms.

5 e-induced cognitive deficits or negative and positive symptoms.

6 lusion correlated with increased severity of positive symptoms.

7 e changes were associated with the degree of positive symptoms.

8 d cingulate gyri correlated with severity of positive symptoms.

9 in negative and depressive symptoms but not positive symptoms.

10 The majority targeted treatment resistant positive symptoms.

11 ning as well as decreases in the severity of positive symptoms.

12 variability in symptom severity or negative/positive symptoms.

13 nse criteria required sustained remission of positive symptoms.

14 no difference between groups in the rate of positive symptoms.

15 impairment) and in those with predominantly positive symptoms.

16 ative symptoms from those with predominantly positive symptoms.

17 ognitive disorganization but not negative or positive symptoms.

18 detect potential correlations between FD and positive symptoms.

19 y of life, symptom severity, or remission of positive symptoms.

20 , symptom severity, and time to remission of positive symptoms.

21 apine without glycine had a 35% reduction in positive symptoms.

22 ributable to the Scale for the Assessment of Positive Symptoms.

23 ymptoms and temporal lobe abnormalities with positive symptoms.

24 ted with transient emergence or worsening of positive symptoms.

25 relevant in the initial development phase of positive symptoms.

26 chronic hospital patients did not differ on positive symptoms.

27 pine was superior to haloperidol in treating positive symptoms.

28 the putamen were associated with more severe positive symptoms.

29 ) than in normal subjects and are related to positive symptoms.

30 d with greater severity of both negative and positive symptoms.

31 pontaneous SCR frequency was associated with positive symptoms.

32 Symptoms and the Scale for the Assessment of Positive Symptoms.

33 showing quetiapine's consistency in reducing positive symptoms.

34 s memory responses were positively linked to positive symptoms.

35 ive rehabilitation, and coping with residual positive symptoms.

36 ng Scale, and the Scale of the Assessment of Positive Symptoms.

37 This deficit correlated with positive symptoms.

38 iated with higher suspiciousness and overall positive symptoms.

39 d antipsychotic drugs only address primarily positive symptoms.

40 impairment, antipsychotic treatment or even positive symptoms.

41 sm was significantly correlated with SCZ and positive symptoms.

42 (BPRS) were used to quantify the severity of positive symptoms.

43 ed response in patients who only experienced positive symptoms.

44 putamen correlated with less improvement in positive symptoms.

45 ed with opposite correlations between RD and positive symptoms.

46 The alpha activity correlated with positive symptoms.

47 e to PFC-dependent correlates of negative or positive symptoms.

48 ot induce clinically significant increase in positive symptoms.

49 ith age, and NAAc correlated negatively with positive symptoms.

50 ences compared with placebo for reduction of positive symptoms (31 179 participants) varied from -0.6

51 d patients showed significant improvement in positive symptoms (52% and 44% reductions from baseline,

52 re as follows: amisulpride for patients with positive symptoms, 537 mg/day and 85.8 mg; aripiprazole,

53 t of which have been shown to correlate with positive symptoms: aberrant learning for neutral cues (a

54 th schizophrenia in symptomatic remission of positive symptoms according to Andreasen, and 24 healthy

55 rome to determine which patients receive the positive symptom advantage of clozapine and the extent o

56 Among patients, change in positive symptoms after amphetamine was significantly as

57 Negative and positive symptoms also worsened (Cohen's d values, 0.45-

58 of medication nonadherence on the return of positive symptoms among recent-onset schizophrenia patie

59 CGI severity and improvement ratings, PANSS positive symptom and general psychopathology subscales,

60 as coded per the Scale for the Assessment of Positive Symptoms and accepted definitions.

61 ion, despite an inverse relationship between positive symptoms and activation.

62 tive and Negative Syndrome Scale factors for positive symptoms and anxiety/depression were greater wi

63 s studied, ketamine and amphetamine produced positive symptoms and euphoria.

64 ces of dopaminergic mechanisms as a cause of positive symptoms and executive deficits.

65 lysis, showing connections with negative and positive symptoms and functional domains.

66 efits of the program included a reduction in positive symptoms and in symptom exacerbations and an in

67 e negatively correlated with the severity of positive symptoms and medication dose in SZ patients.

68 The severity of attenuated positive symptoms and overall functioning were assessed.

69 Clozapine was superior to risperidone for positive symptoms and parkinsonian side effects, but the

70 s and failure to respond, as well as between positive symptoms and production of erroneous responses.

71 ous phasic dopamine release helps to explain positive symptoms and provides a unified explanation for

72 l manifestation, prevents the development of positive symptoms and related neurobiological alteration

73 ting scales (the Scale for the Assessment of Positive Symptoms and the alogia subscale of the Scale f

74 onal outcomes were not entirely dependent on positive symptoms and the development of psychosis, furt

75 a symptoms-and-function definition based on positive symptoms and the modified Global Assessment of

76 ared to both the subjects with predominantly positive symptoms and the normal subjects.

77 ssessed with the Scale for the Assessment of Positive Symptoms and the Scale for the Assessment of Ne

78 ere rated on the Scale for the Assessment of Positive Symptoms and the Scale for the Assessment of Ne

79 ssessed with the Scale for the Assessment of Positive Symptoms and the Scale for the Assessment of Ne

80 al scores on the Scale for the Assessment of Positive Symptoms and the Scale for the Assessment of Ne

81 ssessed with the Scale for the Assessment of Positive Symptoms and the Scale for the Assessment of Ne

82 ia significantly correlated with severity of positive symptoms and thought disorder and with impairme

83 son subjects were evaluated for negative and positive symptoms and underwent comprehensive neuropsych

84 es >=3 using the Scale for the Assessment of Positive Symptoms) and associated psychotic and nonpsych

85 namely enhanced MK-801 psychomotor response (positive symptoms) and decreased working memory (cogniti

86 Three symptom factors-negative symptoms, positive symptoms, and affective symptoms-were all signi

87 the medial temporal lobe was correlated with positive symptoms, and baseline [(11)C]flumazenil VT in

88 s revealed three factors: negative symptoms, positive symptoms, and disorganization.

89 nsolidation in schizophrenia, contributes to positive symptoms, and is a promising novel target for t

90 ing predominance of women, lower severity of positive symptoms, and lower average antipsychotic dose

91 able schizophrenia, predominant NSS, limited positive symptoms, and maintained on stable atypical ant

92 the ES group was negatively correlated with positive symptoms, and positively correlated with negati

93 erms of total symptoms, overall functioning, positive symptoms, and quality of life.

94 ety, negative symptoms, overall functioning, positive symptoms, and social functioning).

95 Nursing home patients had the least severe positive symptoms, and the acutely ill and chronic hospi

96 ation of untreated psychosis, past drug use, positive symptoms, and violent behavior.

97 chizophrenia during symptomatic remission of positive symptoms, and whether potential alterations rel

98 represented dimensions of mania, depression, positive symptoms, anxiety, negative symptoms and disorg

99 (n = 17, 8.5%), which was unrelated to SIPS-positive symptoms, any DSM diagnosis or other clinical c

100 e rehabilitation and training in coping with positive symptoms appear to be promising interventions,

101 t, and all the prodromal features other than positive symptoms are transdiagnostic.

102 d in the illness, correlate with measures of positive symptoms, are consistent with models of disease

103 We conclude that tonic and paroxysmal positive symptoms as well as negative symptoms may be a

104 rovide a novel strategy for the treatment of positive symptoms associated with schizophrenia.

105 gh preceded by reflux (mainly distal), 56% a positive symptom association probability (SAP(C-R (2 min

106 ted temporal associations, with 48% having a positive symptom association probability (SAP(R-C)) for

107 Symptoms and the Scale for the Assessment of Positive Symptoms at 18 months after randomization.

108 greater improvement than control subjects on positive symptoms at all time points and on negative sym

109 al scores on the Scale for the Assessment of Positive Symptoms at baseline and at follow-up.

110 nly if they exhibited one or more attenuated positive symptoms at moderate to severe, but not psychot

111 Symptoms and the Scale for the Assessment of Positive Symptoms) at index hospitalization and quality

112 P group, only the ADS SA was associated with positive symptoms (beta = -0.08; 95% CI, -0.13 to -0.02;

113 ationship between longer DUP and more severe positive symptoms (beta=-0.16, p=4.5x10(-8) ), more seve

114 prediction model was developed and included positive symptoms, bizarre thinking, sleep disturbances,

115 hrenia, especially those that treat not only positive symptoms but also the negative and cognitive sy

116 therapy, clozapine has superior efficacy for positive symptoms but not negative symptoms and is assoc

117 depressive symptoms correlated with that of positive symptoms but not with age, gender, negative sym

118 oduce fairly robust clinical benefit against positive symptoms but typically have minimal therapeutic

119 ntipsychotic drugs (APDs) show efficacy with positive symptoms, but are limited in treating negative

120 ative symptoms at any time after control for positive symptoms, but its effects on positive symptoms

121 of haloperidol over olanzapine for improving positive symptoms, but the benefit was scale-dependent:

122 iated with the transient amphetamine-induced positive-symptom change, as observed in schizophrenia.

123 results suggest that the neural substrate of positive symptoms changes with illness chronicity, and t

124 bles, with end point differences in the BPRS positive-symptom cluster score showing quetiapine's cons

125 condary efficacy variables included the BPRS positive-symptom cluster score, the Modified Scale for t

126 Severity of Illness item; and P = .003, BPRS positive-symptom cluster) differences were identified be

127 , despite an absence of depressive symptoms, positive symptoms, comorbid systemic illnesses, or medic

128 ssions' Severity of Illness Scale as well as positive symptoms compared with those receiving placebo.

129 significantly with risperidone response were positive symptoms, conceptual disorganization, akathisia

130 he diagnosis of FAPS is made on the basis of positive symptom criteria and a longstanding history of

131 ore homogeneous high-risk sample (attenuated positive symptom criteria only, age range of mid-teens t

132 elapse (dCC-NC=0.36 vs dDC-NC=0.02, p=0.04), positive symptoms (dCC-NC=0.15 vs dDC-NC=-0.30, p=0.05)

133 Proximal outcomes were global positive symptoms, delusions, hallucinations, and cognit

134 r schizophrenia with suboptimally controlled positive symptoms despite treatment with antipsychotics.

135 , with the strongest effect observed for the positive symptom dimension, which includes suspiciousnes

136 Symptoms and the Scale for the Assessment of Positive Symptoms divided into 3 domains: psychotic, neg

137 as associated with treatment response in the positive symptom domain in both clinical cohorts (p valu

138 st that patients with minimal improvement in positive symptoms during the first week of treatment wit

139 ost features are transdiagnostic, except for positive symptoms (e.g. paranoia, f = 0.40).

140 personality disorder [healthy aging], mania/positive symptoms [early psychosis]), impaired thought p

141 ate connectivity pattern and the severity of positive symptoms evaluated with the Positive and Negati

142 t (i.e., mediated by differential effects on positive symptoms, extrapyramidal symptoms, or mood).

143 difference between the three SMD groups was positive symptoms (f = 0.30).

144 s the mean change from baseline in the PANSS Positive Symptom Factor Score (PSFS) at week 12, analyse

145 ngs revealed a negative symptom factor and a positive symptom factor.

146 hed expression and disordered relating), two positive symptom factors (bizarre delusions and auditory

147 (two consecutive ratings without significant positive symptoms) for rare allele carriers versus wild

148 (1) a symptoms-only definition based on the positive symptoms from the Scale of Prodromal Symptoms a

149 idate prognostic factors: negative symptoms, positive symptoms, functioning, depressive symptoms, sui

150 he studies examined, MCT was associated with positive symptoms (g = 0.50; 95% CI, 0.34-0.67), delusio

151 than other interventions pooled in reducing positive symptoms (g=0.16).

152 ptoms (g=0.42) and supportive counseling for positive symptoms (g=0.23).

153 rs1036145 showed significant improvement in positive symptoms, general psychopathology, and thought

154 ither SNP, showed significant improvement in positive symptoms, general psychopathology, thought dist

155 g positive outcomes for both functioning and positive symptoms; group 2 (49%) exhibited moderate impa

156 Positive symptoms had the lowest expected influence.

157 ively; P = .01; between-group d = -0.66) and positive symptoms (hallucinations, delusions, disorganiz

158 th schizophrenia in symptomatic remission of positive symptoms have decreased striatal dopamine synth

159 onse, less relapse); for schizophrenia, less positive symptoms/higher depressive symptoms (remission,

160 minergic function, are effective at reducing positive symptoms (i.e. delusions and hallucinations), t

161 ring treatment, the mean score for prodromal positive symptoms improved more in the olanzapine group

162 Positive symptoms in all nonaffective psychoses probands

163 ed with poorer treatment outcome in terms of positive symptoms in both groups.

164 hermore, clozapine was superior in improving positive symptoms in both study groups, but not for nega

165 ments in functional outcome, motivation, and positive symptoms in low-functioning patients with signi

166 study examined the frequency of negative and positive symptoms in nonpsychotic patients with temporal

167 s initiation was associated with more severe positive symptoms in our cohort.

168 work, and default mode network contribute to positive symptoms in patients with schizophrenia.

169 The significant correlations between positive symptoms in schizophrenia and diffusion and NAA

170 is effective in treating negative as well as positive symptoms in schizophrenia resistant to standard

171 a promising strategy to treat cognitive and positive symptoms in schizophrenia.

172 toms of schizophrenia are only effective for positive symptoms in some individuals, and have consider

173 Amphetamine significantly increased positive symptoms in subjects with SCH (19.5 +/- 5.3 vs.

174 ut statistically significant, improvement in positive symptoms in the active rTMS group (p = .047, ef

175 y in schizophrenia predicted the severity of positive symptoms in the disorder, such as hallucination

176 ated deviations in amygdala connectivity and positive symptoms in the psychosis spectrum group.

177 well as between negative and positive (PANSS-Positive) symptoms in influencing functional outcome of

178 predicted abnormal auditory perception (and positive symptoms) in PScz in 3 paradigms.

179 n, that aberrant salience (and the resulting positive symptoms) in schizophrenia may arise, at least

180 thological features manifest behaviorally as positive symptoms (including hallucinations, delusions a

181 he flawed agency judgments characteristic of positive symptoms, including auditory hallucinations and

182 dopamine receptor antagonism in ameliorating positive symptoms, including auditory hallucinations, in

183 ried forward analyses on the sum of selected positive symptom items of the Brief Psychiatric Rating S

184 ent-by-brain structure interactions for BPRS positive symptom items.

185 chizophrenia patients with both negative and positive symptoms (n = 11) and schizophrenia patients wi

186 1) and schizophrenia patients with primarily positive symptoms (n = 11).

187 rom confirmatory factor analysis relating to positive symptoms, negative symptoms of diminished expre

188 tures that can be parsed into three domains: positive symptoms, negative symptoms, and cognitive defi

189 ss a complex symptomatology characterized by positive symptoms, negative symptoms, and cognitive impa

190 ng of the boundaries and connections between positive symptoms, negative symptoms, and role functioni

191 onal solution separated individuals based on positive symptoms, negative symptoms, depression, and fu

192 S share fundamental clinical features (i.e., positive symptoms, negative symptoms, functional deficit

193 groups that separated on primary deficits of positive symptoms, negative symptoms, global functioning

194 the presence of 3 clusters corresponding to positive symptoms; negative symptoms and work functionin

195 ntipsychotic medication in the management of positive symptoms of acute schizophrenia as well as nega

196 ms were significantly more likely to exhibit positive symptoms of psychosis after 24 months.

197 ospitalisation and perceived risk to others, positive symptoms of psychosis, reduced insight into ill

198 and delusions are often grouped together as positive symptoms of psychosis.

199 twork-level alterations were associated with positive symptoms of psychosis.

200 )mania, and contextually misallocated in the positive symptoms of psychosis.

201 nt in social and communication function, and positive symptoms of restricted and repetitive behaviors

202 nt in all medications that effectively treat positive symptoms of schizophrenia (e.g., delusions and

203 hotic drugs (APDs) are effective in treating positive symptoms of schizophrenia (SCZ).

204 nistered Dissociative States Scale (P<.001); positive symptoms of schizophrenia as assessed by the Br

205 ic drugs are widely thought to alleviate the positive symptoms of schizophrenia by antagonizing dopam

206 Positive symptoms of schizophrenia correlated negatively

207 When SAR218645 was tested in models of the positive symptoms of schizophrenia, it reduced head twit

208 f the former appears to track improvement of positive symptoms of schizophrenia, the latter have rece

209 therapy in the treatment of drug-refractory positive symptoms of schizophrenia.

210 , VNS reversed a behavioral correlate of the positive symptoms of schizophrenia.

211 a more general physiologic deficit underlies positive symptoms of schizophrenia.

212 Positive symptoms of speech dysfunction were classified

213 with predominantly negative or predominantly positive symptoms on the basis of their post-drug-washou

214 In general, improvement in positive symptoms over the time interval was associated

215 ed with an increase in the severity of total positive symptoms over time (r=-0.33; df=47; P=0.02), mo

216 in and between group reductions in both BPRS positive symptoms (p = 0.02, d = -0.36; p = 0.008, d = -

217 han in HS (p<0.032), and was associated with positive symptoms (p<0.007), antipsychotic load (p<0.015

218 ody of evidence demonstrates that persistent positive symptoms, particularly delusions, can be improv

219 normalities than subjects with predominantly positive symptoms, particularly in frontal, temporal, an

220 sessed once per test day, while negative and positive symptoms, perceptual alterations, and a number

221 ol for positive symptoms, but its effects on positive symptoms persisted after control for negative s

222 roup was indirect (ie, partially mediated by positive symptoms) (probit coefficient [beta] = 0.12; P

223 Among patients with attenuated positive symptoms, processing speed was related to socia

224 enrolled 75 CHR individuals with attenuated positive symptom psychosis-risk syndrome as defined by t

225 a separate sibpair analysis using scores on positive-symptom (psychotic), negative-symptom (deficit)

226 ions in K(i) correlated with improvements in positive symptoms (r = 0.5, p < 0.05), but not with chan

227 cantly associated with increased severity of positive symptoms (r=0.19; q=0.05) in the psychosis spec

228 dered thought patterns associated with fewer positive symptoms rather than cognitive deficits in the

229 Safety scales included the 4-item Positive Symptom Rating Scale for psychotomimetic sympto

230 cipants met criteria for conversion if their positive symptoms reached the fully psychotic range and

231 Ketamine produced psychotic-like positive symptoms, reductions in working memory and sust

232 The primary outcome was positive symptom relapse and remission, including the pr

233 ols correlated specifically with more severe positive symptoms (rho = -0.77, P = .002).

234 on's disease-adapted scale for assessment of positive symptoms (SAPS-PD) in all patients who received

235 on Rating Scale, Scale for the Assessment of Positive Symptoms, Scale for the Assessment of Negative

236 e ratings of the Scale for the Assessment of Positive Symptoms, Scale for the Assessment of Negative

237 With the positive symptom-scale scores, the marker D6S1960 produc

238 ief Psychiatric Rating Scale total score and positive symptom score, Scale for the Assessment of Nega

239 ically significant treatment effect on PANSS positive symptom scores (beta for change in raloxifene v

240 nsion were related to greater BPRS total and positive symptom scores and longer time hospitalized.

241 nction signal was positively correlated with positive symptom scores during deceptive repayments.

242 elation between VS activity and negative and positive symptom scores in patients.

243 any CSF alteration had significantly higher positive symptom scores than those without alterations (

244 Dyskinetic movement scores correlated with positive symptom scores.

245 The response in the amygdala correlated with positive symptom severity (r = .16, P = .01) but not wit

246 was mainly restricted to the subcortex, with positive symptom severity being associated with midbrain

247 In comparison, positive symptom severity is less strongly correlated wi

248 ted pathway in the functional impairment and positive symptom severity of CHR patients.

249 individuals in early psychosis stages beyond positive symptom severity to investigate specificity rel

250 Higher positive symptom severity was associated with reduced ac

251 onfirmed association to patient delusion and positive symptom severity.

252 0]; P = .03], which persisted over and above positive symptom severity.

253 P < .001), but no correlation was found with positive symptom severity.

254 ity was associated with greater negative and positive symptom severity; a pattern that was also evide

255 in early psychosis and could be involved in positive symptoms severity in males, indicating potentia

256 regions where FA correlated positively with positive symptoms severity.

257 (P < .05); however, other patients with low positive symptoms showed no significant deficits.

258 mptoms (primary outcomes), overall symptoms, positive symptoms, side effects, exacerbation of psychos

259 Positive symptoms (SMD 0.45) improved more than negative

260 pears to have a significant association with positive symptoms, specifically delusions.

261 n difference: -0.24, 95% CI=-0.39 to -0.09), positive symptoms (standardized mean difference: -0.17,

262 augmented AMPH-induced peak changes in PANSS positive symptom subscale and both subjective and object

263 e to week 6 and week 12, mean BPRS total and positive symptom subscale scores were reduced significan

264 sessed by the Brief Psychiatric Rating Scale positive symptoms subscale (P<.001); negative symptoms a

265 dary end points were the change in the PANSS positive symptom subscore, the score on the Clinical Glo

266 not be a sufficient mechanism for explaining positive symptoms such as auditory hallucinations in sch

267 A reflects a sufficient mechanism to explain positive symptoms such as auditory hallucinations.

268 aracteristic of schizophrenia and related to positive symptoms, such as auditory hallucinations.

269 proteins with 6-month follow-up measures of positive symptoms summary (PSS) scores and functional ou

270 Two positive symptoms (suspiciousness and delusions), howeve

271 ess onset (t = -1.355, df = 277, P = 0.177), positive symptoms (t = 0.249, df = 289, P = 0.803), nega

272 longer hospital admissions, and more severe positive symptoms than for individuals who discontinue c

273 ption betel chewers had significantly milder positive symptoms than low-consumption chewers over 1 ye

274 ide stratifications beyond the expression of positive symptoms that cut across illness stages and dia

275 res included the Scale for the Assessment of Positive Symptoms, the Scale for the Assessment of Negat

276 antipsychotic efficacy and rodent models of positive symptoms through antagonism of DA-D2 receptors,

277 was predictive of good treatment response of positive symptoms to antipsychotic drugs.

278 pilepsy and the relationship of negative and positive symptoms to cognition, quantitative magnetic re

279 reductions from the fluphenazine baseline in positive symptoms, total symptoms, and depression.

280 predictive accuracy compared with attenuated positive symptoms used alone.

281 tive rehabilitation and coping with residual positive symptoms was also examined.

282 The severity of negative and positive symptoms was assessed, medications were monitor

283 Severity of positive symptoms was not associated with genetic/famili

284 as seen when the Scale for the Assessment of Positive Symptoms was used but not when the Positive and

285 The expected link of one with positive symptoms was verified, but the link of the othe

286 work for the EOS patients with predominantly positive symptom were highly similar to typically develo

287 However, psychosis-positive symptoms were associated with connections of va

288 lutamate and amphetamine-induced subclinical positive symptoms were detected.

289 antipsychotic efficacy and those that model positive symptoms were employed and we found that L-Gova

290 nd bipolar disorder patients, the models for positive symptoms were largely non-overlapping between t

291 Negative but not positive symptoms were more prevalent in temporal lobe e

292 Clozapine levels and positive symptoms were not associated with either behavi

293 elations in a subgroup of patients with high positive symptoms were significantly reduced from age 14

294 1)H-MRSI) and rating scales for negative and positive symptoms were used to study 36 patients with sc

295 Among women who screened positive, symptoms were recorded in 43% of the charts, d

296 ent as a complex combination of negative and positive symptoms, which vary enormously from individual

297 associated with more hallucinations and more positive symptoms, while lower relative glucose metaboli

298 fects in individual patients correlated with positive symptoms, while the pattern similarity to NMDA

299 -0.126; 95% CI, -0.190 to -0.062; P < .001); positive symptoms with work skills (B, -0.059; 95% CI, -

300 nt improvements in negative symptoms without positive symptom worsening.